JP2023541601A5 - - Google Patents

Info

Publication number
JP2023541601A5
JP2023541601A5 JP2023515861A JP2023515861A JP2023541601A5 JP 2023541601 A5 JP2023541601 A5 JP 2023541601A5 JP 2023515861 A JP2023515861 A JP 2023515861A JP 2023515861 A JP2023515861 A JP 2023515861A JP 2023541601 A5 JP2023541601 A5 JP 2023541601A5
Authority
JP
Japan
Prior art keywords
antibody fragment
compound according
human
fap
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023515861A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023541601A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/075009 external-priority patent/WO2022053651A2/en
Publication of JP2023541601A publication Critical patent/JP2023541601A/ja
Publication of JP2023541601A5 publication Critical patent/JP2023541601A5/ja
Pending legal-status Critical Current

Links

JP2023515861A 2020-09-10 2021-09-10 Ｆａｐに対する抗体フラグメント Pending JP2023541601A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20195428.6 2020-09-10
EP20195428 2020-09-10
PCT/EP2021/075009 WO2022053651A2 (en) 2020-09-10 2021-09-10 Antibody fragment against fap

Publications (2)

Publication Number Publication Date
JP2023541601A JP2023541601A (ja) 2023-10-03
JP2023541601A5 true JP2023541601A5 (enExample) 2024-10-10

Family

ID=72470247

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515861A Pending JP2023541601A (ja) 2020-09-10 2021-09-10 Ｆａｐに対する抗体フラグメント

Country Status (10)

Country Link
US (1) US20230381350A1 (enExample)
EP (1) EP4211171A2 (enExample)
JP (1) JP2023541601A (enExample)
KR (1) KR20230093251A (enExample)
CN (1) CN116438200A (enExample)
AU (1) AU2021341508A1 (enExample)
CA (1) CA3192236A1 (enExample)
IL (1) IL301285A (enExample)
MX (1) MX2023002850A (enExample)
WO (1) WO2022053651A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023203135A1 (en) * 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
CN120309735A (zh) * 2024-01-15 2025-07-15 迈威(上海)生物科技股份有限公司 重组抗fap抗体及其应用
CN119735700B (zh) * 2024-11-25 2025-09-23 江苏集萃崛创生物科技研究所有限公司 一种car-t细胞及其应用
WO2026122400A1 (en) * 2024-12-03 2026-06-11 Amgen Inc. Bispecific lymphotoxin b receptor binding proteins

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004287875B2 (en) 2003-11-05 2011-06-02 Bausch + Lomb Ireland Limited Modulators of cellular adhesion
AR050902A1 (es) 2004-04-27 2006-12-06 Glaxo Group Ltd Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
RS53830B1 (sr) 2009-04-30 2015-06-30 Glaxo Group Limited Indazoli supstituisani oksazolom kao inhibitori pi3-kinaze
WO2011040972A1 (en) * 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Anti-fibroblast activation protein antibodies and methods and uses thereof
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
SG10202010119TA (en) 2010-11-15 2020-11-27 Abbvie Inc NAMPT And Rock Inhibitors
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
NO2773633T3 (enExample) 2011-11-02 2017-12-30
JOP20190001B1 (ar) 2011-11-03 2022-03-15 Bayer Pharma AG عقار أولي معتمد على جليكول عديد إثيلين من أدرينومدالين واستخدامه
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
EP2854812A1 (en) 2012-05-24 2015-04-08 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada
RU2611010C2 (ru) 2012-07-26 2017-02-17 Глаксо Груп Лимитед 2-(Азаиндол-2-ил)бензимидазолы в качестве ингибиторов PAD4
DK2839860T3 (da) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
LT2928881T (lt) 2012-12-07 2018-06-11 F. Hoffmann-La Roche Ag Nauji piridino dariniai
MX363437B (es) 2012-12-13 2019-03-22 Novartis Ag Pirimido-4,5-b]-quinolina-4,5 (3h,10h)-dionas como supresoras de mutacion sin sentido.
EP2935249B1 (en) 2012-12-19 2018-12-12 Novartis AG Autotaxin inhibitors
SG11201506018PA (en) 2013-02-14 2015-08-28 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
CN105143220B (zh) 2013-03-07 2018-06-22 豪夫迈·罗氏有限公司 吡唑衍生物
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
BR112015027394A8 (pt) 2013-05-02 2018-01-30 Hoffmann La Roche derivados de pirrolo[2,3-d]pirimidina como agonistas de receptor cb2
EP3011339A4 (en) 2013-06-18 2017-01-25 Aminomedix Inc. Compositions and methods for the preparation of kidney protective agents comprising amifostine and amino acids
CA2926215A1 (en) 2013-10-06 2015-04-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified pseudomonas exotoxin a
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3092256B1 (en) 2014-01-10 2022-05-18 Birdie Biopharmaceuticals Inc. Compounds and compositions for immunotherapy
CA2935012A1 (en) 2014-01-10 2015-07-16 F. Hoffmann-La Roche Ag Aryl sultam derivatives as rorc modulators
GB201402006D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
MX378281B (es) 2014-04-25 2025-03-10 Pf Medicament Conjugado farmaco-anticuerpo y su uso para el tratamiento contra el cancer.
PE20161475A1 (es) 2014-05-14 2017-01-08 Pfizer Pirazolopiridinas y pirazolopirimidinas
TWI714528B (zh) 2014-05-14 2021-01-01 瑞士商諾華公司 甲醯胺衍生物
WO2016016242A1 (en) 2014-08-01 2016-02-04 Boehringer Ingelheim International Gmbh Substituted oxetanes and their use as inhibitors of cathepsin c
NO2721710T3 (enExample) 2014-08-21 2018-03-31
US10189788B2 (en) 2014-09-09 2019-01-29 Bayer Pharma Aktiengesellschaft Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
KR102441634B1 (ko) 2014-10-15 2022-09-13 베링거 인겔하임 인터내셔날 게엠베하 알도스테론 신타아제 억제제
CA2960794A1 (en) 2014-11-07 2016-05-12 F. Hoffmann-La Roche Ag Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2
EA201791363A1 (ru) 2014-12-19 2018-01-31 Байер Фарма Акциенгезельшафт Пиразолопиридинамины в качестве ингибиторов mknk1 и mknk2
MX2017011991A (es) * 2015-03-18 2018-05-28 Stemimmune Incorporated Terapia virica con una combinacion de anticuerpos.
UY36586A (es) 2015-03-26 2016-10-31 Bayer Pharma AG Heterociclilmetiltienouracilos y uso de los mismos
TN2017000465A1 (en) 2015-05-06 2019-04-12 Bayer Pharma AG The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
MX2018002006A (es) 2015-08-20 2018-06-19 Boehringer Ingelheim Int Benzamidas apareadas novedosas.
EP3298022B1 (en) 2015-08-20 2019-06-05 Boehringer Ingelheim International GmbH Novel annelated phenoxyacetamides
CN108602816A (zh) 2015-10-09 2018-09-28 艾伯维公司 用于治疗囊性纤维化的新颖化合物
EP3371311B1 (en) 2015-11-06 2021-07-21 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
TN2018000198A1 (en) 2015-12-29 2019-10-04 Pfizer Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
CN106928365B (zh) * 2015-12-30 2020-09-29 广西医科大学 一种FAP纳米抗体Nb36
CN109071632B (zh) 2016-02-05 2022-12-30 奥里尼斯生物科学私人有限公司 靶向性治疗剂及其用途
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3455245A2 (en) 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutic targeting of non-cellular structures
WO2017194783A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
CR20180581A (es) 2016-06-10 2019-02-11 Bayer Pharma AG Complejos radio-farmacéuticos
US20200306244A1 (en) 2016-06-22 2020-10-01 Novartis Ag Wnt inhibitors for use in the treatment of fibrosis
CN109311886B (zh) 2016-06-23 2021-11-09 豪夫迈·罗氏有限公司 [1,2,3]三唑并[4,5-d]嘧啶衍生物
CN110114368B (zh) 2016-10-24 2024-08-02 奥睿尼斯生物科学私人有限公司 靶向突变干扰素-γ及其用途
WO2018109607A1 (en) 2016-12-16 2018-06-21 Pfizer Inc. Glp-1 receptor agonists and uses thereof
MX2019008626A (es) 2017-01-20 2019-09-19 Pfizer Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl).
EP3576765B1 (en) 2017-02-06 2025-07-16 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
SMT202200490T1 (it) 2017-04-18 2023-01-13 Medimmune Ltd Coniugati di pirrolobenzodiazepina
CN117924493A (zh) 2017-08-09 2024-04-26 奥里尼斯生物科学有限公司 Clec9a结合剂及其用途
EP3665201A4 (en) 2017-08-09 2021-06-02 Orionis Biosciences, Inc. CD8 BINDERS
EP3664829A4 (en) 2017-08-09 2021-05-05 Orionis Biosciences, Inc. LIAISON OFFICERS AT PD-1 AND PD-L1
US12655186B2 (en) 2018-01-26 2026-06-16 Orionis Biosciences, Inc. Chimeric protein comprising anti-XCR1 antibody and modified interferon alpha 2
CA3090406A1 (en) * 2018-02-05 2019-08-08 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
KR20260100427A (ko) 2018-03-28 2026-06-29 오리오니스 바이오사이언시즈 인코포레이티드 이작용성 단백질 및 이의 작제물
EP3833391A4 (en) 2018-08-08 2022-08-10 Orionis Biosciences, Inc. ANTI-SIRP1ALPHA CHIMERIC PROTEINS AND USES THEREOF

Similar Documents

Publication Publication Date Title
Li et al. 225Ac-H4py4pa for targeted alpha therapy
Sugiura et al. Radiolabeling strategies for tumor-targeting proteinaceous drugs
AU2022202439B2 (en) Mono-,di- or polysaccharide used as metal inhibitor in the preparation of 68Ga-chelate-functionalized targeting agent
Nikula et al. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry
Couturier et al. Cancer radioimmunotherapy with alpha-emitting nuclides
Barbet et al. Radiolabeled antibodies for cancer imaging and therapy
Miederer et al. Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications
US4460561A (en) Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
EP1465670B1 (en) Labeling targeting agents with gallium-68 and gallium-67
Fritzberg Advances in 99mTc-labeling of antibodies
Isabel M. Prata Gallium-68: a new trend in PET radiopharmacy
AU2005259258B2 (en) Radionuclides for medical use
Liu et al. Radiolabeling morpholinos with 90Y, 111In, 188Re and 99mTc
Liu et al. Radiolabeled integrin αvβ3 antagonists as radiopharmaceuticals for tumor radiotherapy
Tolmachev Choice of radionuclides and radiolabelling techniques
Hiltunen Search for new and improved radiolabeling methods for monoclonal antibodies: a review of different methods
Srivastava Therapeutic radionuclides: making the right choice
Virzi et al. Recombinant metallothionein-conjugated streptavidin labeled with 188Re and 99mTc
Uehara et al. The integrity of the disulfide bond in a cyclic somatostatin analog during 99mTc complexation reactions
Bensimon et al. Antibody radiolabeling
Randhawa Development of sulfur-rich chelators for incorporation of soft and intermediate theranostic radiometals into radiopharmaceuticals
HK40054111A (en) Mono-, di- or polysaccharide used as metal inhibitor in the preparation of 68ga-chelate-functionalized targeting agent
Pougoue Ketchemen et al. Preclinical characterization of 3p-C-DEPA-NCS and 3p-C-DEPA-TFP-PEG4 as potential Actinium-225 bifunctional chelators using DOTA-NCS and macropa-NCS as benchmarks
Abrunhosa et al. Radiopharmaceuticals: Development and Main Applications
Mather Current directions in radiopharmaceutical research